Type 2 diabetes mellitus is a complex and heterogeneous disorder. The pathogenesis involves multiple mechanisms which contribute to hyperglycaemia, most notably impaired insulin secretion by pancreatic β-cells, reduced glucose uptake by skeletal muscle and adipose tissue (peripheral insulin resistance) and increased hepatic glucose production. Although basal insulin secretion may remain within the normal range, the meal-time insulin response is blunted or delayed in patients with type 2 diabetes mellitus, which causes post-prandial hypoglycaemia.
BACKGROUND: The more rapid onset of action and the shorter half-life of repaglinide may reduce the p...
WOS: 000243353400012PubMed ID: 17211567In this study, we investigated the effects of combining prepr...
Its a meglitinide analog is an oral symptom designed to common hour aldohexose excursions. Through n...
Type 2 diabetes mellitus is a complex and heterogeneous disorder. The pathogenesis involves multiple...
Type 2 diabetes mellitus is a complex and heterogeneous disorder. The pathogenesis involves multiple...
Dept. of Endocrinology and Metabolism, University Hospital Maastricht, The Netherlands. bwo@sint.azm...
As the prevalence of type 2 diabetes continues to rise, new drug therapies will need to be explored ...
OBJECTIVE — Repaglinide, a novel antidiabetic agent that has a rapid onset and short du-ration of ac...
This article reviews the clinical evidence and pharmacological rationale for repaglinide, a prandial...
OBJECTIVE - To examine the dose-related pharmacodynamics and pharmacokinetics of a single preprandia...
To compare the effect of Repaglinide vs Glimepiride on glucose- and meal-induced insulin secretion a...
Repaglinide is a short-acting insulin secretagogue used for the reduction in postprandial glucose le...
The combination of oral antidiabeticdrugs and bedtime insulin is cur-rently regarded as the first-li...
The role of postprandial hyperglycemia (PPHG) in diabetes mellitus is being increasingly recognized....
OBJECTIVE—To assess the effects of incremental doses of repaglinide on postprandial insulin and gl...
BACKGROUND: The more rapid onset of action and the shorter half-life of repaglinide may reduce the p...
WOS: 000243353400012PubMed ID: 17211567In this study, we investigated the effects of combining prepr...
Its a meglitinide analog is an oral symptom designed to common hour aldohexose excursions. Through n...
Type 2 diabetes mellitus is a complex and heterogeneous disorder. The pathogenesis involves multiple...
Type 2 diabetes mellitus is a complex and heterogeneous disorder. The pathogenesis involves multiple...
Dept. of Endocrinology and Metabolism, University Hospital Maastricht, The Netherlands. bwo@sint.azm...
As the prevalence of type 2 diabetes continues to rise, new drug therapies will need to be explored ...
OBJECTIVE — Repaglinide, a novel antidiabetic agent that has a rapid onset and short du-ration of ac...
This article reviews the clinical evidence and pharmacological rationale for repaglinide, a prandial...
OBJECTIVE - To examine the dose-related pharmacodynamics and pharmacokinetics of a single preprandia...
To compare the effect of Repaglinide vs Glimepiride on glucose- and meal-induced insulin secretion a...
Repaglinide is a short-acting insulin secretagogue used for the reduction in postprandial glucose le...
The combination of oral antidiabeticdrugs and bedtime insulin is cur-rently regarded as the first-li...
The role of postprandial hyperglycemia (PPHG) in diabetes mellitus is being increasingly recognized....
OBJECTIVE—To assess the effects of incremental doses of repaglinide on postprandial insulin and gl...
BACKGROUND: The more rapid onset of action and the shorter half-life of repaglinide may reduce the p...
WOS: 000243353400012PubMed ID: 17211567In this study, we investigated the effects of combining prepr...
Its a meglitinide analog is an oral symptom designed to common hour aldohexose excursions. Through n...